Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1997 1
2015 1
2016 1
2018 1
2021 3
2022 2
2023 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 Study Group. Dunkle LM, et al. Among authors: adelglass jm. N Engl J Med. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15. N Engl J Med. 2022. PMID: 34910859 Free PMC article. Clinical Trial.
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
Áñez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Plested JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301–Pediatric Expansion Study Group. Áñez G, et al. Among authors: adelglass jm. JAMA Netw Open. 2023 Apr 3;6(4):e239135. doi: 10.1001/jamanetworkopen.2023.9135. JAMA Netw Open. 2023. PMID: 37099299 Free PMC article. Clinical Trial.
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial.
Áñez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Plested JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 – Pediatric Expansion Study Group. Áñez G, et al. Among authors: adelglass jm. medRxiv [Preprint]. 2022 Sep 21:2022.09.20.22279903. doi: 10.1101/2022.09.20.22279903. medRxiv. 2022. PMID: 36172135 Free PMC article. Preprint.
The efficacy assessment of a self-administered immunotherapy protocol.
Schaffer FM, Garner LM, Ebeling M, Adelglass JM, Hulsey TC, Naples AR. Schaffer FM, et al. Among authors: adelglass jm. Int Forum Allergy Rhinol. 2016 Feb;6(2):148-55. doi: 10.1002/alr.21653. Epub 2015 Oct 14. Int Forum Allergy Rhinol. 2016. PMID: 26467843 Free PMC article.
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial.
Bennett C, Chau G, Clayton E, Chu L, Alvarez J, Hidalgo AB, Palanpurwala K, Plested JS, Zhu M, Cloney-Clark S, Cai Z, Kalkeri R, Hegazy K, Smith K, Neal S, Noriega F, Mallory RM, Adelglass JM; 2019nCoV-314 Study Investigators. Bennett C, et al. Among authors: adelglass jm. J Infect. 2025 Feb;90(2):106428. doi: 10.1016/j.jinf.2025.106428. Epub 2025 Jan 26. J Infect. 2025. PMID: 39874991 Free article. Clinical Trial.
The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Lorenc ZP, Adelglass JM, Avelar RL, Baumann L, Beer KR, Cohen JL, Cox SE, Dayan SH, Dover JS, Downie JB, Draelos ZD, Goldman MP, Gross JE, Joseph JH, Kaufman-Janette J, Moy RL, Nestor M, Schlessinger J, Smith SR, Weiss RA. Lorenc ZP, et al. Among authors: adelglass jm. Aesthet Surg J. 2021 Nov 12;41(12):1423-1438. doi: 10.1093/asj/sjaa382. Aesthet Surg J. 2021. PMID: 33944913 Free PMC article. Clinical Trial.
Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis.
Bronsky EA, Aaronson DW, Berkowitz RB, Chervinsky P, Graft D, Kaiser HB, Moss B, Nathan RA, Pearlman DS, Ratner PH, Adelglass JM, Southern DL, van Bavel J, Hampel F, Stricker WE, Fourré JA, Cuss FM, Nolop KB. Bronsky EA, et al. Among authors: adelglass jm. Ann Allergy Asthma Immunol. 1997 Jul;79(1):51-6. doi: 10.1016/S1081-1206(10)63084-0. Ann Allergy Asthma Immunol. 1997. PMID: 9236500 Clinical Trial.
Corrigendum to: The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Lorenc ZP, Adelglass JM, Avelar RL, Baumann L, Beer KR, Cohen JL, Cox SE, Dayan SH, Dover JS, Downie JB, Draelos ZD, Goldman MP, Gross JE, Joseph JH, Kaufman-Janette J, Moy RL, Nestor M, Schlessinger J, Smith SR, Weiss RA. Lorenc ZP, et al. Among authors: adelglass jm. Aesthet Surg J. 2021 Nov 12;41(12):1494-1495. doi: 10.1093/asj/sjab230. Aesthet Surg J. 2021. PMID: 34189562 Free PMC article. No abstract available.
11 results